e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
40.70
UNCHANGED
Streaming Delayed Price
Updated: 2:59 PM EDT, Apr 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders
April 07, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
April 07, 2026
From
Ademi LLP
Via
GlobeNewswire
Why Biogen Stock Got Mashed on Monday
↗
April 06, 2026
Its first-quarter expenses will be notably higher than anticipated.
Via
The Motley Fool
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
April 06, 2026
In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis...
Via
MarketMinute
Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate
↗
April 02, 2026
Via
Chartmill
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Q4 2025 Earnings Beat Amid Mixed Revenue Results
↗
February 24, 2026
Via
Chartmill
Topics
Earnings
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Pairs Strong Growth with Bullish Chart Setup
↗
February 24, 2026
Via
Chartmill
The Coiled Spring: Why Small-Caps are Poised for a Generational Productivity-Led Surge
April 03, 2026
As of April 3, 2026, the American equity market is witnessing a historic "Great Rotation" that many analysts believe could define the latter half of the decade. For the first time in over a...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Halper Sadeh LLC is Investigating Whether APLS, CNTA, EQH, VYNE are Obtaining Fair Deals for their Shareholders
April 02, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
April 01, 2026
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive...
Via
MarketMinute
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy
↗
January 22, 2026
Via
Chartmill
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
March 31, 2026
From
Kahn Swick & Foti
Via
Business Wire
Why Biogen Stock Sank While the Market Soared on Thursday
↗
March 31, 2026
It's reaching into its coffers for a $5.6 billion acquisition.
Via
The Motley Fool
Halper Sadeh LLC is Investigating Whether APLS, CNTA, BIRD, WBD are Obtaining Fair Deals for their Shareholders
March 31, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
March 31, 2026
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to...
Via
MarketMinute
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
March 31, 2026
Via
Chartmill
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
March 31, 2026
Via
AB Newswire
These stocks are making the most noise in today's session.
↗
March 31, 2026
Via
Chartmill
Which stocks are experiencing notable movement on Tuesday?
↗
March 31, 2026
Via
Chartmill
The market is filled with gapping stocks in Tuesday's session.
↗
March 31, 2026
Via
Chartmill
Discover the top movers in Tuesday's pre-market session.
↗
March 31, 2026
Via
Chartmill
APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
March 31, 2026
From
Halper Sadeh LLC
Via
Business Wire
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
↗
March 21, 2026
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
March 02, 2026
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis (APLS) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Apellis (APLS) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
February 23, 2026
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
February 19, 2026
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
February 10, 2026
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert